上海兆维 2026 年 8 月展会预告

展会信息

上海兆维科技发展有限公司（Hongene Biotech）将于 2026 年 8 月 5-7 号参加由中国生化制药工业协会主办，在天津于家堡洲际酒店举行的第十届中国（天津）核酸药物大会，展位号 #A18。

近年来，核酸药物产业全面迈入产业化落地周期。依托精准的治疗优势，核酸药物已成为继小分子、抗体药后的第三大创新赛道，产业增长潜力持续释放。

目前全球已有 26 款核酸药物获批上市，国内获批产品达 6 款，标志着国内核酸产业正在进入临床转化与规模化生产并行的全新发展阶段。

作为国内核酸领域标杆行业盛会，由中国生化制药工业协会主办的中国（天津）核酸药物大会已成功举办多届。

8 月 5-7 日，第十届中国（天津）核酸药物大会将在天津举办。本届大会聚焦核酸创新与产业化落地，围绕核酸技术管线开发、工艺放大瓶颈、质量合规管控、上下游产业链协同等核心议题展开深度研讨。

展会信息

上海兆维科技发展有限公司（Hongene Biotech）将于 2026 年 8 月 17-19 号参加由 Hanson Wade Group 主办，在美国·波士顿举行的 5th Annual Oligonucleotides CMC & Analytical Development Summit，展位号 #1。

Scaling DNA & Large RNA Construct Production, Analytics, & Quality Control for cGMP Compliant Vaccines, Therapeutics, & RNA-Based Cell & Gene Therapies

As oligonucleotide therapeutics continue to advance across ASOs, siRNA, gRNA, and increasingly complex conjugates, analytical development, process development, quality control and CMC teams face growing pressure to deliver robust, scalable and regulatory-ready programs.

From oligonucleotide characterization, impurity profiling, LC-MS analytics, control strategy development, and comparability assessments through to GMP manufacturing, organizations must align analytical and CMC strategies with increasing FDA and global regulatory expectations.

Returning to Boston, the 5th Oligonucleotide Analytical Development & CMC Summit brings together 90+ leaders spanning Analytical Development, CMC, Process Development, Quality Control, Analytical Science, Regulatory Affairs, and Manufacturing to share practical case studies and establish best practices for bringing high-quality oligonucleotide therapeutics to market.

展会信息

上海兆维科技发展有限公司（Hongene Biotech）将于 2026 年 8 月 19-21 号参加由 Hanson Wade Group 主办，在美国·波士顿举行的 6th Annual Oligonucleotides for CNS Summit，展位号 #1。

Harnessing Maturing Oligonucleotide Technologies to Unlock Undruggable CNS Targets with Enhanced RNA Chemistry & Innovative Delivery

Oligonucleotide R&D is accelerating, driven by advances in brain shuttle technologies, RNA chemistry, and growing clinical validation from leaders such as Alnylam Pharmaceuticals, Stoke Therapeutics, and Ionis Pharmaceuticals. At the same time, major investments, including Novartis into Arrowhead Pharmaceuticals, Biogen into City Therapeutics, and Roche into Manifold Bio, underscore CNS as a key frontier for these technologies, unlocking previously undruggable targets.

Building on last year’s momentum, the 6th Annual Oligonucleotides for CNS Summit will bring together 90+ experts across CNS biology, oligo chemistry, RNA science, and DMPK. Attendees will explore the latest innovations advancing nucleic acid therapies for neurodegenerative, neuromuscular, rare, epileptic, and neurodevelopmental disorders.

This summit uniquely connects stakeholders at the intersection of oligonucleotides and CNS. Join leaders from Eli Lilly, Dyne Therapeutics, Creyon Bio, and more for three days of collaboration to accelerate RNA-targeted CNS therapies.

展会信息

上海兆维科技发展有限公司（Hongene Biotech）将于 2026 年 8 月 25-28 号参加由 IS3NA 主办，在西班牙·巴塞罗那举行的 IRT 2026 - XXVI International Round Table on Nucleosides, Nucleotides and Nucleic Acids，展位号 #4。

This meeting is organized by the International Society on Nucleosides, Nucleotides and Nucleic Acids (IS3NA) and is one of the most prestigious international conferences focused on nucleosides and oligonucleotides. This meeting is a part of a series of symposia that have been organized worldwide every two years since 1974. In this occasion, the IRT Symposium will be celebrated together with XIV Meeting on Nucleic Acids and Nucleosides (RANN XIV) organized by the Spanish Network on Nucleic Acids.

The conference will bring together researchers on nucleic acid chemistry, biology and medicine to discuss cutting-edge science. Leading researchers worldwide will be invited to present their valuable results on special topics such as therapeutic oligonucleotides, nucleosides with antiviral, anticancer or antibiotic properties, synthesis and structure of nucleic acids and non-canonical nucleic acids.